Meropenem-induced drug hypersensitivity syndrome in children: a case report

Published on Jul. 31, 2026Total Views: 60 times Total Downloads: 13 times Download Mobile

Author: LI Wen ¹ LI Gen ¹ JIANG Yongxian ¹ HU Siqi ¹  ZHANG Bo ²

Affiliation: 1.Department of Pharmacy, Sichuan Provincial Maternity and Child Health Care Hospital, Chengdu 610041, China 2.Department of Pharmacy, Yibin Second Hospital of Traditional Chinese Medicine, Yibin 644000, Sichuan Province, China

Keywords: Meropenem Drug hypersensitivity syndrome Adverse reactions Pseudomonas aeruginosa Children

DOI: 10.12173/j.issn.1005-0698.202512011

Reference: Li W, Li G, Jiang YX, et al. Meropenem-induced drug hypersensitivity syndrome in children: a case report[J]. Chinese Journal of Pharmacoepidemiology, 2026, 35(7): 836-840. DOI: 10.12173/j.issn.1005-0698.202512011.[Article in Chinese]  Copied

Abstract
Full-text
References

Abstract

This report describes a case of meropenem-induced hypersensitivity syndrome in a pediatric patient. The patient, a 10-month-old male, had multi-system (skin, respiratory tract, and hematologic) infection caused by Pseudomonas aeruginosa, with clinical manifestations including fever, subcutaneous induration, rash, diarrhea, convulsions, and anuria. After admission, the patient received sequential anti-infective therapy including cefotaxime 0.5 g ivd q8h, meropenem 0.2 g ivd q8h, cefoperazone-sulbactam 0.5 g ivd q8h, and ceftazidime 0.5 g ivd q12h. After relapse and re-administration of meropenem (22 days after the initial treatment), the patient exhibited classic hypersensitivity reaction syndrome features (generalized rash, multi-site lymphadenopathy, fever, hepatic impairment, and leukocytosis), accompanied by reactivation of Epstein-Barr virus. Symptomatic management with hydrocortisone sodium succinate and immunoglobulin was initiated upon discontinuation of meropenem, resulting in clinical improvement. Naranjo's Assessment Scale evaluation indicated a "highly probable association." This case suggests that meropenem may induce drug hypersensitivity reactions with prolonged latency periods in children, necessitating heightened clinical vigilance, early identification, and comprehensive management.

Full-text

Please download the PDF version to read the full text: download

References

1. 朱晓洁, 刘检, 张予阳. 2010年英文期刊罕见药源性疾病的分析[J]. 药物流行病学杂志, 2011, 20(11): 599-602.ZhuXJ, LiuJ, ZhangYY. Analysis of rare drug-induced diseases in English journals in 2010[J]. Chinese Journal of Pharmacoepidemiology, 2011, 20(11): 599-602. DOI:10.19960/j.cnki.issn.1005-0698.2011.11.013.

2. HamaN, AbeR, GibsonA, et al. Drug-induced hypersensitivity syndrome (DIHS)/drug reaction with eosinophilia and systemic symptoms ( DRESS): clinical features and patho-genesis[J]. J Allergy Clin Immunol Pract, 2022, 10(5):1155-1167. DOI: 10.1016/J.JAIP.2022.02.004.

3. StirtonH, ShearNH, Dodiuk-GadRP. Drug reaction with eosinophilia and systemic symptoms(DReSS)/drug-induced hypersensitivity syndrome (DiHS)-readdressing the DReSS[J]. Biomedicines, 2022,10(5): 999. DOI: 10.3390/biomedicines10050999.

4. ShioharaT, MizukawaY. Drug-induced hypersensitivity syndrome (DiHS)/drug reaction with eosinophilia and systemic symptoms (DRESS): an update in 2019[J]. Allergol Int, 2019, 68(3): 301-308. DOI: 10.1016/j.alit.2019. 03.006.

5. KardaunSH, SekulaP, Valeyrie-AllanoreL, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study[J]. Br J Dermatol, 2013, 169(5):1071-1080. DOI: 10.1111/bjd.12501.

6. ShioharaT, KanoY. Drug reaction with eosinophilia and systemic symptoms (DRESS): incidence, pathogenesis and management[J]. Expert Opin Drug Saf, 2017, 16(2):139-147. DOI: 10.1080/14740338.2017.1270940.

7. KimDH, KohYI. Comparison of diagnostic criteria and determination of prognostic factors for drug reaction with eosinophilia and systemic symptoms syndrome[J]. Allergy Asthma Immunol Res, 2014, 6(3): 216-221. DOI: 10. 4168/aair.2014.6.3.216.

8. HusainZ, ReddyBY, SchwartzRA. DRESS syndrome: Part I. Clinical perspectives[J]. J Am Acad Dermatol, 2013, 68(5): 693.el-e14. DOI: 10.1016/j.jaad.2013.01.033.

9. 中国医师协会皮肤科医师分会变态反应性疾病专业委员会. 药物超敏反应综合征诊治专家共识[J]. 中华皮肤杂志, 2018, 51(11): 787-790.Chinese Dermatologist Association, Allergic Disease Committee of Chinese Dermatologist Association. Expert consensus on the diagnosis and treatment of drug-induced hypersensitivity syndrome[J]. Chinese Journal of Dermatology, 2018, 51(11): 787-790. DOI: 10.3760/cma.j.issn.0412-4030.2018. 11.002.

10. NaranjoCA, BustoU, SellersEM, et al. A method for estimating the probability of adverse drug reactions[J]. Clin Pharmacol Ther, 1981, 30(2): 239-245. DOI: 10.1038/clpt.1981.154.

11. 唐春梅, 杨思芸, 詹阳洋, 等. 基于FAERS数据库的3种碳青霉烯类药物不良反应信号挖掘研究[J]. 中南药学, 2021, 12: 2576-2581.TangCM, YangSY, ZhanYY, et al. Adverse drug reaction signals of three carbapenems based on FAERS database mining[J]. Central South Pharmacy, 2021, 12: 2576-2581. DOI: 10.7539/j.issn. 1672-2981. 2021.12.019.

12. Prados-CastañoM, Piñero-SaavedraM, Leguísamo-MillaS, et al. DRESS syndrome induced by meropenem[J]. Allergol Immunopathol (Madr), 2014, 43(2): 232-235. DOI: 10.1016/j.aller.2013.12.004.

13. SongG, ChengMQ, LiR, et al. Drug-induced hypersensitivity syndrome with high procalcitonin levels due to piperacillin/tazobactam and meropenem: a case report[J]. Front Med (Lausanne), 2022, 9: 951714. DOI: 10.3389/fmed.2022.951714.

14. de CamargoMB, Ribeiro-VazI, de Cássia BergamaschiC, et al. Antibiotics and drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: analysis of Brazilian pharmacovigilance registries[J]. Pharmacoepidemiol Drug Saf, 2025, 34(4): e70128. DOI: 10.1002/pds.70128.

15. PicardD, JanelaB, DescampsV, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): a multiorgan antiviral T cell response[J]. Sci Transl Med, 2010, 2(46): 46-62. DOI: 10.1126/scitranslmed.3001116.

16. Ben-SaidB, Arnaud-ButelS, RozieresA, et al. Allergic delayed drug hypersensitivity is more frequently diagnosed in drug reaction, eosinophilia and systemic symptoms (DRESS) syndrome than in exanthema induced by beta-lac-tam antibiotics[J]. Dermatol Sci, 2015, 80(1): 71-74. DOI: 10.1016/j.jdermsci.2015.07.014.

17. KinoshitaY, SaekiH, AsahinaA, et al. Drug-induced hypersensitivity syndrome in Japan in the past 10 years based on data from the relief system of the Pharmaceuticals and Medical Devices Agency[J]. Allergol int, 2017, 66(2):363-365. DOI: 10.1016/j.alit. 2016.09.003.

18. Komatsu-FujiiT, ChinukiY, NiiharaH, et al. The thymus and activation-regulated chemokine (TARC) level in serum at an early stage of a drug eruption is a prognostic biomarker of severity of systemic inflammation[J]. Allergol Int, 2018, 67(1): 90-95. DOI: 10.1016/j.alit.2017.06.001.

19. ChuMT, ChangWC, PaoSC, et al. Delayed drug hypersensitivity reactions: molecular recognition, genetic susceptibility, and immune mediators[J]. Biomedicines, 2023, 11(1): 177. DOI: 10.3390/biomedicines11010177.

20. RutkowskiK, TaylorC, WagnerA. HLA B62 as a possible risk factor for drug reaction with eosinophilia and systemic symptoms to piperacillin/tazobactam[J]. J Allergy Clin Immunol Pract, 2017, 5(3): 829-830. DOI: 10.1016/j.jaip.2016.10.008.